NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $85.10 +0.83 (+0.98 %) (As of 01/18/2019 06:35 AM ET)Previous Close$84.27Today's Range$83.96 - $85.1952-Week Range$78.95 - $116.49Volume914,977 shsAverage Volume1.10 million shsMarket Capitalization$11.47 billionP/E Ratio15.76Dividend Yield2.52%Beta0.9 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Receive DGX News and Ratings via Email Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:DGX Previous Symbol CUSIP74834L10 Webwww.questdiagnostics.com Phone973-520-2700Debt Debt-to-Equity Ratio0.63 Current Ratio1.15 Quick Ratio1.09Price-To-Earnings Trailing P/E Ratio15.76 Forward P/E Ratio13.44 P/E Growth1.73 Sales & Book Value Annual Sales$7.71 billion Price / Sales1.50 Cash Flow$7.4584 per share Price / Cash Flow11.41 Book Value$36.35 per share Price / Book2.34Profitability EPS (Most Recent Fiscal Year)$5.40 Net Income$772 million Net Margins11.30% Return on Equity15.71% Return on Assets7.56%Miscellaneous Employees45,000 Outstanding Shares136,070,000Market Cap$11.47 billion OptionableOptionable Quest Diagnostics (NYSE:DGX) Frequently Asked Questions What is Quest Diagnostics' stock symbol? Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX." How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics? Quest Diagnostics declared a quarterly dividend on Thursday, November 29th. Shareholders of record on Tuesday, January 15th will be paid a dividend of $0.53 per share on Wednesday, January 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date is Monday, January 14th. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.50. View Quest Diagnostics' Dividend History. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics declared that its Board of Directors has approved a share repurchase plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 7.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's leadership believes its stock is undervalued. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Inc (NYSE:DGX) posted its quarterly earnings results on Tuesday, October, 23rd. The medical research company reported $1.68 EPS for the quarter, hitting the consensus estimate of $1.68. The medical research company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.95 billion. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The company's quarterly revenue was up 1.8% compared to the same quarter last year. During the same period last year, the business posted $1.38 EPS. View Quest Diagnostics' Earnings History. When is Quest Diagnostics' next earnings date? Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Quest Diagnostics. How can I listen to Quest Diagnostics' earnings call? Quest Diagnostics will be holding an earnings conference call on Thursday, February 14th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8884550391. What guidance has Quest Diagnostics issued on next quarter's earnings? Quest Diagnostics updated its FY18 earnings guidance on Thursday, November, 29th. The company provided earnings per share (EPS) guidance of $6.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.56. The company issued revenue guidance of ~$7.57 billion, compared to the consensus revenue estimate of $7.62 billion. What price target have analysts set for DGX? 18 equities research analysts have issued 12 month price targets for Quest Diagnostics' stock. Their predictions range from $90.00 to $121.00. On average, they anticipate Quest Diagnostics' share price to reach $104.25 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price. View Analyst Price Targets for Quest Diagnostics. What is the consensus analysts' recommendation for Quest Diagnostics? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quest Diagnostics. What are Wall Street analysts saying about Quest Diagnostics stock? Here are some recent quotes from research analysts about Quest Diagnostics stock: 1. According to Zacks Investment Research, "Quest Diagnostics has underperformed its industry in the past six months. After a disappointing third quarter performance, we are concerned about factors like unfavorable changes in prescription drug monitoring, vitamin D testing and hepatitis C testing marketplace that can dent growth going forward. Also, in the last-reported quarter, a rise in patient concession impacted the top line, resulting in a decline in revenue per requisition. Tough competition and reimbursement issues are other concerns. On a brighter note, Quest Diagnostics is currently refocusing on diagnostic information services business and disciplined capital deployment. The company’s’ acquisitions and collaborations with hospitals and integrated delivery networks (the latest being Provant Health) continue to act as major growth drivers. We are upbeat about the company entering into a strategic partnership agreement with UnitedHealthcare." (1/17/2019) 2. Canaccord Genuity analysts commented, "We stick with our BUY rating, and lower our PT from $105 to $98, based on 14.3x our 2020 adj. EPS estimate." (11/30/2018) Has Quest Diagnostics been receiving favorable news coverage? News headlines about DGX stock have trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quest Diagnostics earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. Who are some of Quest Diagnostics' key competitors? Some companies that are related to Quest Diagnostics include Laboratory Corp. of America (LH), ELEKTA AB/ADR (EKTAY), Guardant Health (GH), Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT) and PotNetwork (POTN). Who are Quest Diagnostics' key executives? Quest Diagnostics' management team includes the folowing people: Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44) Who are Quest Diagnostics' major shareholders? Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.16%), Sit Investment Associates Inc. (0.12%), Retirement Systems of Alabama (0.09%), USS Investment Management Ltd (0.08%), Boston Advisors LLC (0.04%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics. Which major investors are selling Quest Diagnostics stock? DGX stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., Denali Advisors LLC, Gulf International Bank UK Ltd, DNB Asset Management AS, Advisors Capital Management LLC, Louisiana State Employees Retirement System, First American Trust FSB and Boston Advisors LLC. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics. Which major investors are buying Quest Diagnostics stock? DGX stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, State of Alaska Department of Revenue, Oakbrook Investments LLC, USS Investment Management Ltd, Kavar Capital Partners LLC, CX Institutional, Capital Investment Advisors LLC and CenturyLink Investment Management Co. View Insider Buying and Selling for Quest Diagnostics. How do I buy shares of Quest Diagnostics? Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quest Diagnostics' stock price today? One share of DGX stock can currently be purchased for approximately $85.10. How big of a company is Quest Diagnostics? Quest Diagnostics has a market capitalization of $11.47 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe. What is Quest Diagnostics' official website? The official website for Quest Diagnostics is http://www.questdiagnostics.com. How can I contact Quest Diagnostics? Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected] MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)Community Ranking: 1.8 out of 5 ()Outperform Votes: 371 (Vote Outperform)Underperform Votes: 661 (Vote Underperform)Total Votes: 1,032MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?